TD Cowen Downgrades Repare Therapeutics (RPTX) to Hold

TD Cowen analyst Marc Frahm downgraded Repare Therapeutics (NASDAQ: RPTX) from Buy to Hold.

The analyst comments "Repare reported Q3 net income of $3MM and $113MM in cash. Repare agreed to be acquired by XenoTherapeutics for an estimated $1.82/share (dependent on cash at closing) + CVR for any further licensing revenue. We see little risk to closing, ascribe minimal value to the CVR, and anticipate shares trading only minimally above the estimated acquisition price. Moving to Hold."

For an analyst ratings summary and ratings history on Repare Therapeutics click here. For more ratings news on Repare Therapeutics click here.

Shares of Repare Therapeutics closed at $1.65 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Bernstein on China Online Beauty: Very Weak July Performance
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)